Metastatic Multiple Myeloma to the Skin

TR Number



Journal Title

Journal ISSN

Volume Title




Cutaneous involvement of multiple myeloma (MM) is uncommon, typically occurs in late stage disease, and is a poor prognostic indicator with an approximate eight month median survival. We present a 51-year-old man with relapsed lambda light chain MM who developed abrupt asymptomatic skin metastases. Biopsy revealed a dermis replete of atypical plasma cells, positive for CD138 and CD45. In situ hybridization confirmed lambda light chain restriction. Despite rescue antimyeloma therapy with the anti-CD38 drug daratumumab, he rapidly declined clinically and succumbed to the disease four weeks after presentation. A standard treatment approach for cutaneous MM does not currently exist; however, various techniques to detect cytogenetic abnormalities are emerging and will provide additional prognostic value and direct individualized therapy.




Alex C. Holliday, Mohammed I. Khan, Sean E. Mazloom, Rahul N. Chavan, and Douglas J. Grider, “Metastatic Multiple Myeloma to the Skin,” Case Reports in Dermatological Medicine, vol. 2019, Article ID 7930123, 3 pages, 2019. doi:10.1155/2019/7930123